title: Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.
abstract: OBJECTIVE
  As most patients with acute myeloid leukemia (AML) with morphologic complete remission (CR) ultimately relapse, better predictors for outcome are needed. Recently, Cheson et al suggested using cytogenetic remission (CRc) as part of the criteria for CR. To our knowledge, ours is the first relatively large study evaluating the usefulness of CRc attained immediately following induction chemotherapy.
  
  
  METHODS
  We included AML patients treated on Cancer and Leukemia Group B front-line studies with cytogenetic samples obtained at diagnosis and at the first day of documented CR following induction. Patients with abnormal cytogenetics at diagnosis, and normal cytogenetics at CR (NCR; n = 103) were compared with those with abnormal cytogenetics both at diagnosis and at CR (ACR; n = 15) for overall survival (OS), disease-free survival (DFS), and cumulative incidence of relapse (CIR). Cox proportional hazards models determined the prognostic significance of cytogenetics at CR, adjusting for other covariates.
  
  
  RESULTS
  Clinical features were similar for both groups, with the exception of favorable cytogenetics [t(8;21), inv(16)/t(16;16), t(15;17)] at diagnosis, which was more frequent (P =.03) in the NCR group. Median follow-up was 3.1 years (range, 1.0 to 11.4 years). ACR patients had significantly shorter OS (P =.006) and DFS (P =.0001), and higher CIR (P =.0001). In multivariable models, the NCR and ACR groups were predictors for OS (P =.03), DFS (P =.02), and CIR (P =.05). The relative risk of relapse or death was 2.1 times higher for ACR patients than for NCR patients (95% CI, 1.1 to 3.9).
  
  
  CONCLUSIONS
  Our data suggest that converting to normal karyotype at the time of first CR is an important prognostic indicator and support the use of CRc as a criterion of CR in AML.
authors.affiliation: Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA. marcucci-1@medctr.osu.edu
authors.forename: Guido
authors.initials: G
authors.lastname: Marcucci
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Mrózek
authors.forename: Amy S
authors.initials: AS
authors.lastname: Ruppert
authors.forename: Kellie J
authors.initials: KJ
authors.lastname: Archer
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Pettenati
authors.forename: Nyla A
authors.initials: NA
authors.lastname: Heerema
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Carroll
authors.forename: Prasad R K
authors.initials: PR
authors.lastname: Koduru
authors.forename: Jonathan E
authors.initials: JE
authors.lastname: Kolitz
authors.forename: Lisa J
authors.initials: LJ
authors.lastname: Sterling
authors.forename: Colin G
authors.initials: CG
authors.lastname: Edwards
authors.forename: John
authors.initials: J
authors.lastname: Anastasi
authors.forename: Richard A
authors.initials: RA
authors.lastname: Larson
authors.forename: Clara D
authors.initials: CD
authors.lastname: Bloomfield
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D002869:Chromosome Aberrations; D018572:Disease-Free Survival; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate